NAMS
NewAmsterdam Pharma Company N.V.
Healthcare — Biotechnology
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Strong Buy
1.4 / 5
14 analysts
$24.16
$-0.16 (-0.66%)
Target:
$49.73
(105.8%)
Price History
52-Week Range
Sign in to add NAMS to a watchlist or set price alerts.
Fundamentals
| Market Cap | $4.11B |
| P/E Ratio (TTM) | - |
| Forward P/E | -27.65 |
| EPS (TTM) | $-1.78 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 2.10% |
| ROE | -29.49% |
| Debt/Equity | 0.00 |
| Recommendation | Strong Buy 1.4 |
| Analyst Target | $49.73 |
| Analysts | 14 |
| Next Earnings | Aug 5, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 81.8 |
| Beta | 0.08 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $42.21 |
| 52-Week Low | $18.70 |
| 50-Day Avg | $32.68 |
| 200-Day Avg | $33.56 |
| Avg Volume | $1.29M |
| Volume | 856.0K |
Performance Analysis
NEUTRALNAMS presents a mixed picture with both positive and negative indicators.
~
Trading at 23% of its 52-week range.
-
RSI at 81.8 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Modest revenue growth of 2.1% year-over-year.
+
Wall Street consensus is "Strong Buy" from 14 analysts.
+
Average analyst target of $49.73 implies 105.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:21 UTC
Back to Screener Export Report